Figure 3.

Treatment with lenvatinib and sensitized lymphocytes reduces apoptosis-related gene expression levels. (A) Effect of lenvatinib treatment on VEGFR mRNA expression level. (B) Effect of treatment with sensitized lymphocytes on PDGFR mRNA expression level. (C) Effect of lenvatinib treatment on RET mRNA expression level. (D) Effect of treatment with lenvatinib plus sensitized lymphocytes on KIT mRNA expression level. Expression of each gene was calculated relative to the expression of β-actin and the results are expressed as the n-fold difference relative to β-actin. Data are presented as the mean ± standard deviation of triplicate samples. One-way analysis of variance revealed significant differences. **P<0.01 vs. the control. VEGFR, vascular endothelial growth factor receptor; PDGFR, platelet-derived growth factor receptor; RuCa, rat uterine cancer adenocarcinoma; ACHN, human kidney adenocarcinoma cell line; 786-0, renal carcinoma cell line.